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Purpose: Telotristat etiprate, a tryptophan hydrox-
ylase inhibitor, was previously evaluated in a Phase II
randomized, placebo-controlled clinical trial in pa-
tients with carcinoid syndrome (CS) and diarrhea not
adequately controlled by octreotide. The objective of
the current study was to characterize the symptom
experiences of patients participating in that trial.
Methods: Consenting patients participated in one-
on-one, qualitative interviews focused on eliciting
symptoms they had experienced in association with
their CS diagnosis and recollection of symptom changes
they experienced while participating in the Phase II trial.
Findings: Among the 23 patients who participated
in the previous 4-week dose-escalation study, 16 were
eligible for interviews and 11 participated in the
present study. The median time from study completion
to the interview was 31 months; 4 of 11 patients were
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April 2016trial at the time of interview. All of the patients
(100%) described diarrhea as a symptom of CS, with
effects on the emotional, social, and physical aspects of
their lives. Improvement in diarrhea during the study
was described by 82% of participants, and was very
impactful in several patients. Results led to the design
and implementation of a larger interview program in
Phase III and helped to establish a deﬁnition of
clinically meaningful change for the clinical develop-
ment program.
Implications: The diarrhea associated with CS can
have a large impact on daily lives, and patient interviews
can characterize and capture clinically meaningful im-
provements with treatment. ClinicalTrials.gov Identiﬁer:
NCT00853047. (Clin Ther. 2016;38:759–768) & 2016
The Authors. Published by Elsevier HS Journals, Inc.
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Clinical TherapeuticsINTRODUCTION
Neuroendocrine tumors (NETs) are thought to arise
from neuroendocrine cells and are often found in the
gastrointestinal tract; these tumors occur in 2 per
100,000 persons.1 Approximately 3 in 10 people with
NETs will develop symptoms known as carcinoid
syndrome (CS).2 Patients with CS generally have
advanced, metastatic disease and a survival rate
lower than that in patients without CS.3 Common
symptoms of CS include diarrhea; ﬂushing of the
upper chest, neck, and face; abdominal pain;
difﬁculty breathing; and heart valve dysfunction.4
Because CS is relatively rare, there is little experi-
ence in formally characterizing the condition with
standardized patient-reported outcomes question-
naires. Furthermore, clinical trials in CS have small
sample sizes, making it difﬁcult to capture statistically
signiﬁcant and clinically meaningful changes with
standardized instruments. In this situation, careful
review of individual responses becomes especially
important, and an interview approach in which the
patient can provide a ﬁrst-hand description of their
clinical trial experience is particularly valuable.
Telotristat etiprate is a tryptophan hydroxylase
inhibitor developed to treat CS by reducing the pro-
duction of serotonin within the metastatic neuroendo-
crine tumor cell. Initial evidence of efﬁcacy was obtained
in a 4-week placebo-controlled Phase II clinical study of
telotristat etiprate.5 In that study, patients were treated
in escalating-dose cohorts, and were randomly assigned
in a 3:1 ratio to receive either telotristat etiprate or
placebo. Clinical response (deﬁned as at least a 50%
reduction in bowel movement frequency for at least 2
weeks) was observed in 5 of 18 patients (28%) treated
with telotristat etiprate compared with 0 of 5 patients
on placebo. There was only 1 overall evaluation of the
patient experience, a weekly question (with a “yes” or
“no” answer) about the presence of adequate relief of
gastrointestinal symptoms of CS. Adequate relief was
reported in 10 of 18 telotristat etiprate–treated patients
(56%) during at least 1 of the ﬁrst 4 weeks of treatment,
compared with zero patients on placebo.
While these observations clearly suggested that telotri-
stat etiprate has biological activity, key questions re-
mained as to the clinical relevance of these ﬁndings.
Furthermore, the optimal strategy to assess patient-
reported outcomes in Phase III clinical development was
unclear. To help address these issues, retrospective inter-
views of Phase II clinical trial participants were performed.760The objectives of the interviews were to character-
ize the participants’ CS experiences and to identify the
important changes they experienced in their symptoms
during the clinical trial of telotristat etiprate, during
the 4-week, blinded, dose-escalation phase and/or the
open-label extension phase.PATIENTS AND METHODS
Participants
All recruiting sites from the Phase II clinical trial
(LX1606.202)5 were invited to join the present
qualitative interview study, and 2 of the 8 sites
chose to participate. A member of each site’s study
staff contacted potential participants to explain the
purpose, procedures, beneﬁts, and risks of the present
interview-based study using a standardized recruit-
ment script. If the patient was interested in participat-
ing, the site’s staff member documented eligibility and
obtained written informed consent and the participant
was scheduled for an interview. All study procedures
were approved by an institutional review board.
Participants meeting the following inclusion criteria
were eligible for the study: participation in the
previous telotristat etiprate Phase II clinical trial5; 18
years of age or older; able to participate in a one-on-
one telephone interview; able to read, speak, and
understand English and complete all study assess-
ments; and willing and able to provide written
informed consent before the interview. Participants
with a cognitive or other impairment (eg, vision or
hearing) that would have interfered with completing
the interview were not eligible for the study.
Interview Procedures
Before each participant’s telephone interview, he or she
received a packet that contained an introductory letter, the
European Organization for Research and Treatment of
Cancer (EORTC) Gastrointestinal NET questionnaire (GI.
NET-21),6,7 the EORTC Quality of Life (QOL) Ques-
tionnaire (QLQ-C30; EORTC 2012),8 and a Sociodemo-
graphic and Clinical Characteristics form. The question-
naires were in a sealed envelope and participants were
directed not to open these materials until instructed to do
so by the interviewer. Participants were asked to return
the materials at the conclusion of the interview.
Trained and experienced interviewers, blinded to
treatment arm, conducted the one-on-one interviews
over the telephone using a prescripted interviewVolume 38 Number 4
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experiences. The interview began with conﬁrmation of
the patient having previously provided written in-
formed consent, followed by an overall explanation
of the study; the interview then moved into a pre-
scripted discussion of the patient’s experiences with
symptoms of CS. The interviews were audio-recorded
and then subsequently transcribed.
Questionnaires and Forms
The EORTC GI.NET-217 is a 21-item self-reported
questionnaire module supplemental to the EORTC
QLQ-C30,8 a 30-item questionnaire assessing the
QOL of patients with cancer. The GI.NET-21 com-
prises questions assessing disease symptoms, adverse
events with treatment, body image, disease-related
worries, social functioning, communication, and sex-
uality. These measures were scored according to the
developer’s guidelines.
The Sociodemographic and Clinical Characteristics
form was used for documenting the participants’ self-
reported information on age, race, employment status,
education, and current CS symptoms; this information
was used for assisting with interpretation of the results
of individual interviews.
Staff members from the clinical sites were asked to
complete a clinical form for each participant who
provided informed consent and who completed an
interview. The clinical form documented information
such as tumor site, concurrent medications, and time
since diagnosis. The information from the EORTC
measures and the clinical forms was used for describ-
ing the sample and assisting with interpretation of the
results of the interviews.
Data Analysis
Data from the qualitative interviews were analyzed
with a content analysis approach using qualitative
data analysis software (ATLAS.ti version 5.2).9 A
coding dictionary, based on the themes and concepts
that emerged during the interviews, was developed to
group words and phrases provided by the interview
participants into key themes, attributes, concepts, and
relationships.10,11
The principal investigator (H.L.G.) conducted an
internal training with the team member(s) who were
coding the transcripts to ensure that the meaning and
purpose of each code were understood, in turn to
ensure consistency in coding of the transcripts. TheApril 2016interview transcripts were independently coded by 2
team members (J.K. and P.A.), which was followed by
comparison and reconciliation whenever differences
occurred. Coded text was associated with qualitative
output tables that identiﬁed and categorized partic-
ipants’ responses.
The key themes and concepts that were identiﬁed
were entered into a saturation grid, with each case
serving as a column and each concept serving as a row.
Concepts identiﬁed in each interview were analyzed,
with the goal of comparing and tallying the amount of
novel information that was observed in each subse-
quent interview. Descriptive statistics (mean, SD,
frequency) were used for characterizing the sample in
terms of sociodemographic and clinical characteristics.RESULTS
Sample Description
A total of 11 participants were interviewed for the
study between December 20, 2012, and February 15,
2013, and 10 of the interview participants returned all
of the postinterview study materials. Reported socio-
demographic characteristics (Table I) and clinical
disease characteristics (Table II) are based on these
10 participants. The calculated mean time between
end of participation in the telotristat etiprate core
study and this study interview was 29.5 months.
Site staff at the telotristat etiprate study sites also
provided clinical information on the participants
(Table III). All of the participants (100%) had NETs
that had metastasized; the most commonly reported
metastatic site was the liver (n ¼ 9 [82%]). Four of the
11 participants (36%) were in the open-label phase of
the telotristat etiprate clinical trial at the time of their
interviews. A majority of the participants (n ¼ 9
[82%]) were on long-acting octreotide treatment and
had received, on average, 1 injection in the past month.
Two participants (18%) had received embolizations
since exiting the telotristat etiprate clinical trial.
EORTC QLQ-30 and GI.NET-21
On the EORTC measures, higher global health
scores represent better QOL, and high scores on the
functional scale represent a higher level of functioning;
however, higher scores on the symptom scales repre-
sent more symptoms. Participants in this study had
scores reﬂecting poorer QOL, symptoms, and func-
tioning than the general population, with mean global761
Table I. Participant-reported sociodemographic
characteristics at the time of questionnaire
completion (N ¼ 10*).
Participant Characteristic Value
Age, y
Mean (SD) 57.0 (7.1)




Hispanic or Latino, no. (%) 0
Race, no. (%)
White 10 (100)
Employment status,† no. (%)
Employed full-time 4 (40.0)
Employed part-time 1 (10.0)
Retired 3 (30.0)
Disabled 3 (30.0)
Highest level of education, no. (%)
Secondary/high school 2 (20.0)
Some college 1 (10.0)
College degree 3 (30.0)
Postgraduate degree 4 (40.0)
*One participant did not return the postinterview study
materials.
†One participant indicated both employed part time
and disabled.
Table II. Participant-reported clinical charac-
teristics at the time of questionnaire
completion (N ¼ 10*).
Clinical Characteristic Value
General health state in past week, no. (%)
Very good 1 (10.0)
Good 3 (30.0)
Fair 6 (60.0)
Number of bowel movements in past 24 h
Mean (SD) 8.3 (5.5)
Median (range) 5.5 (3–20)





Number of daily cutaneous ﬂushing episodes in
past 24 h
Mean (SD) 0.5 (0.8)
Median (range) 0.0 (0–2)




*One participant did not return the postinterview study
materials.
Clinical Therapeuticshealth status/QOL, physical functioning, role func-
tioning, and emotional functioning scores of 56.7,
82.7, 71.7, and 80.0, respectively, compared with
general population’s reference values of 71.2, 89.8,
84.7, and 76.3, respectively.12 Of the symptom scales
assessed, diarrhea, had the highest reported mean
(70.0; general population reference, 7.0), followed
by fatigue (48.9; general population reference, 24.1),
and insomnia (36.7; general population reference,
21.8). Other mean symptom scale scores ranged
between 10.0 and 53.3, with constipation and
nausea exhibiting the lowest values. Table IV
summarizes participants’ mean and median scores on
the EORTC QLQ-30 during the interview study.
For the GI.NET-21, a higher score was equivalent
to worse symptoms or problems. In general, partic-
ipants scored below a mean of 50 across all subscales.762Table V summarizes the participants’ responses on the
GI.NET-21 during the interview study.
Most Commonly Reported Symptoms Attributed
to CS
Table VI summarizes the symptoms attributed to
CS. Participants generally described diarrhea as the
most severe and frequent symptom. Most participants
were actively seeking treatment to decrease their
diarrhea and had varying levels of success with
multiple medications. Urgency related to diarrhea
was described as severe, and participants mentioned
difﬁculty controlling their bowels, which often was
associated with bowel-related accidents. The fre-
quency of diarrhea was usually the participants’ main
concern. Improvement in this symptom was most
commonly described as a reduction in the frequency
of bowel movements. Several participants describedVolume 38 Number 4
Table III. Clinician-reported clinical characteristics
at the time of questionnaire completion
(N ¼ 11).
Clinical Characteristics Value
Neuroendocrine tumor has metastasized, no. (%)
Yes 11 (100)
On octreotide treatment, no. (%)
No 2 (18.2)
Yes 9 (81.8)
Number of octreotide injections in past month
Mean (SD) 0.8 (0.4)
Median (range) 1.0 (0–1)
Value of most recent urinary 5-HIAA test (mg/24 h)*
Mean (SD) 25.4 (26.7)
Median (range) 19.0 (3–68)








*Three participants had missing values. One partici-
pant, whose results were reported in alternative units
(5280 ng/mL), was not included in the calculation of
the mean.
†The normal range for the urinary 5-HIAA test is 2 to
6 mg/24 h.17
‡Often performed on liver metastases in the setting of
progressive disease.
H.L. Gelhorn et al.being embarrassed or anxious about dining out in
public and/or traveling due to their diarrhea, and
needing to be aware of bathroom locations when they
did leave the house.
All of the participants (n ¼ 11 [100%]) reported
experiencing abdominal pain, while 6 of the partic-
ipants (55%) also reported having abdominal cramp-
ing, a symptom that the participants reported as
distinct from abdominal pain. Both pain and cramp-
ing were symptoms that participants experienced daily
and caused some of the participants to take pain
medications due to the severity.
Nine of the participants (82%) reported that they
experienced ﬂushing. Their experiences were consistent
in some ways; all of them reported redness/ﬂushing inApril 2016the face and most of them reported that these
experiences were not painful or very noticeable. Four
of the participants mentioned that they knew that they
were experiencing ﬂushing only when someone asked
about it during an episode. Nine participants (82%)
reported being tired or experiencing fatigue. Partic-
ipants described having to nap or rest during the day
because they felt exhausted and had no energy. One
participant mentioned being able to sleep 20 of 24
hours. This symptom was described as severe, and
participants felt fatigued even after a full night of rest.
Some participants noted that sleep interruptions, often
related to diarrhea, would cause them to be tired the
next day. Fatigue also affected participants’ ability to
complete daily activities, such as work and family
obligations, and caused irritability and problems with
mental acuity.
Impact of CS
Several of the participants discussed speciﬁc effects of
CS symptoms. The most common concern described
was an unwillingness, or inability, to travel or partic-
ipate in hobbies or usual activities due to concerns
about bowel accidents and/or loss of control of bodily
functions (eg, diarrhea, gas, belching). A few mentioned
an impaired ability to sleep associated with waking up
to go to the bathroom, and effects on mood (including
irritability) that were particularly noticeable as their
long-acting somatostatin analogue wore off near the
end of the dosing interval (generally after 3–4 weeks).
Reported Changes in CS
In response to queries about changes in sympto-
matology that the patients experienced speciﬁcally
during the Phase II clinical trial of telotristat etiprate,
there were 21 symptoms reported by between 1 and 9
of the participants. It should be noted that 1 partic-
ipant on telotristat etiprate 350 mg tid indicated that
there was no change in any symptoms during the
clinical trial, and another participant on telotristat
etiprate 150 mg TID noted that he or she did not
recall his or her symptom experience during the trial.
Symptoms reported by 3 or more participants are
summarized in Table VI. The most commonly
reported changes were in diarrhea, abdominal pain,
ﬂushing, and abdominal cramping. There were 6
participants who reported a large number (ie, 43)
of changes in symptoms, while the remaining 3
participants reported changes in only 1 or 2763
Table IV. EORTC QLQ-C30 (N ¼ 10).*
Questionnaire Variable Value
Global health status/QOL†
Mean (SD) 56.7 (11.7)
Median (range) 50.0 (42–75)
Functional scales‡
Physical functioning
Mean (SD) 82.7 (13.8)
Median (range) 80.0 (60–100)
Role functioning
Mean (SD) 71.7 (20.9)
Median (range) 66.7 (33–100)
Emotional functioning
Mean (SD) 80.0 (21.6)
Median (range) 83.3 (25–100)
Cognitive functioning
Mean (SD) 61.7 (31.5)
Median (range) 58.3 (0–100)
Social functioning
Mean (SD) 53.3 (15.3)
Median (range) 58.3 (33–67)
Symptom scales/items§
Fatigue
Mean (SD) 48.9 (26.3)
Median (range) 44.4 (0–89)
Nausea and vomiting
Mean (SD) 10.0 (16.1)
Median (range) 0.0 (0–50)
Pain
Mean (SD) 25.0 (23.9)
Median (range) 33.3 (0–67)
Dyspnea
Mean (SD) 26.7 (21.1)
Median (range) 33.3 (0–67)
Insomnia
Mean (SD) 36.7 (36.7)
Median (range) 33.3 (0–100)
Appetite loss
Mean (SD) 26.7 (30.6)
Median (range) 33.3 (0–100)
Constipation
Mean (SD) 0.0 (0.0)
Median (range) 0.0 (0–0)
Diarrhea
Mean (SD) 70.0 (29.2)





Mean (SD) 53.3 (39.1)
Median (range) 50.0 (0–100)
*Scores range from 0 to 100, with a high scale score
representing a higher response level. Each subscale is
based on the after items: global health status/quality
of life (QOL) (items 29 and 30), physical functioning
(1–5), role functioning (6 and 7), emotional
functioning (21–24), cognitive functioning (20 and
25), social functioning (26 and 27), fatigue (10, 12,
and 18), nausea and vomiting (14 and 15), pain (9 and
19), dyspnea (8), insomnia (11), appetite loss (13),
constipation (16), diarrhea (17), and ﬁnancial
difﬁculties (28).
†A high score on the global health status/QOL subscale
represents a high quality of life.
‡A high score on the functional subscale represents a
high/healthy level of functioning.
§A high score is equivalent to worse or more problems.
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764symptoms in response to treatment with telotristat
etiprate. No worsening of symptoms was described
with telotristat etiprate use.
Among the transcripts, one of the most informative
was from a patient who had an interruption in therapy.
Her experience has been described elsewhere.13 She
believed that her relief of diarrhea was too great to be
explained by a placebo effect: “I don’t think anybody
that’s had as violent diarrhea as I have had for as many
years as I have had it could psychologically change
with a placebo.” Her therapy was stopped for about a
week because of a rash that was initially suspected to
be related to study drug. Therapy was resumed after
the investigator attributed the rash to another cause.
The patient recalled this episode spontaneously in great
detail, expressing concerns about the potential of not
being able to continue receiving a medication that had
been so important to her. As indicated in the electronic
diary, in the ﬁrst week during the study, the bowel
movement frequency had an initial reduction from
8.2 to 3 or 4 per day. This frequency returned
to baseline during the interruption of therapy, and
came back down to 4 per day with the resumption
of treatment. She was on telotristat etiprate 500 mg
TID.Volume 38 Number 4




Mean (SD) 17.8 (10.7)
Median (range) 16.7 (0–33)
GI symptoms scale
Mean (SD) 28.7 (19.9)
Median (range) 23.3 (7–60)
Treatment-related symptoms scale
Mean (SD) 20.8 (26.8)
Median (range) 11.1 (0–67)
Social function scale
Mean (SD) 37.8 (24.1)
Median (range) 27.8 (11–78)
Disease related worries
Mean (SD) 38.9 (24.1)
Median (range) 33.3 (11–100)
Symptoms
Muscle/bone pain symptom
Mean (SD) 46.7 (35.8)
Median (range) 33.3 (0–100)
Sexual function
Mean (SD) 41.7 (29.5)
Median (range) 50.0 (0–67)
Information/communication function
Mean (SD) 6.7 (14.1)
Median (range) 0.0 (0–33)
Body image
Mean (SD) 16.7 (36.0)
Median (range) 0.0 (0–100)
*Scores range from 0 to 100, with a high scale score
representing a higher response level. Each subscale is
based on the after items: endocrine scale (items 31–
33); gastrointestinal scale (34–38); treatment scale
(39, 40, and 46); social function scale (42, 44, and
49); disease related worries scale (41, 43, and 47);
muscle/bone pain (48), sexual function (51),
information/communication function (50), and body
Image (45).
†A high score is equivalent to worse or more problems.
Table VI. Most common participant-reported
symptoms associated with carcinoid dis-
ease in Z3 participants, and reported
changes during the lx1606.202 study,
by recall (N = 11). Data are given as









Diarrhea 11 (100) 9 (82)
Abdominal pain 11 (100) 5 (45)
Flushing 9 (82) 4 (36)






7 (63) 1 (9)
Abdominal
cramping
6 (55) 4 (36)
Feeling sick 5 (45) 0
Wheezing 5 (45) 0




Blood in stool 3 (27) 0
Dehydration 3 (27) 2 (18)
Lack of appetite 3 (27) 2 (18)
Hot ﬂashes/night
sweats
3 (27) 1 (9) each
H.L. Gelhorn et al.Another relevant transcript was from a patient on
telotristat etiprate 250 mg TID whose reduction in
bowel movement frequency in the electronic diary
developed gradually but also reached a magnitude ofApril 2016at least 30% in weeks 3 and 4. He said, “once I
started seeing some improvement I naturally had a
sense of well-being, I felt good, I felt like, you know, I
wanted to go outside again, I wanted to go uptown to
the grocery store with my wife.” He spoke about
being less embarrassed about his condition (not
having to buy adult diapers), and about seeing a
greater effect of concurrent medications; he felt that a
slowing of gastrointestinal transit time allowed him to
obtain pain relief from his analgesic medication.
Bowel movement frequency data from all 11
patients from the double-blind period and extension
were reviewed, and overall a mean reduction in bowel
movement frequency of Z1.2 per day was associated765
Clinical Therapeuticswith more positive descriptions of the clinical trial
experience. Given the characteristics of this popula-
tion, the data support the concept of a 30% reduction
being used for a responder analysis in Phase III.DISCUSSION
The results of the present study provide an under-
standing of how diarrhea, a primary symptom of CS,
affects the lives of patients with CS and show that it
affects social functioning (eg, difﬁculty with travel)
and sleep (eg, waking up at night to have a bowel
movement), and that diarrhea may be related to
fatigue or tiredness in some patients. This improved
understanding of the impact of diarrhea supports the
clinical importance of reducing bowel movement
frequency as a primary end point in CS clinical trials.
Use of diarrhea as a symptomatic end point in clinical
trials is consistent with regulatory guidance on the use
of patient-reported outcomes as clinical end points.14
The small sample size and the fact that only a
subset of patients in the treatment study were inter-
viewed preclude any ﬁrm conclusions about the
efﬁcacy of telotristat etiprate. However, the patients’
descriptions suggest that treatment may help to
improve several symptoms, and they provide support
for a patient interview approach in assessing the
clinical relevance of symptom relief, in combination
with other patient-reported outcomes measures, in
future studies. Key concepts for consideration as end
points in future CS clinical trials should include
diarrhea, abdominal pain, abdominal cramping, ﬂush-
ing, and gas. Other symptom concepts that may be
worthy of consideration include lack of appetite,
dehydration, fatigue/tiredness, and sleep interruptions.
The results of the interviews further support the
selection of ﬂushing and abdominal pain as secondary
end points in Phase III clinical trial programs, and they
suggest a role for the EORTC-QLQ-C30 and EORTC
QLQ-GI.NET21. Relevant concepts in the QLQ-GI.
NET21 include diarrhea (item 17), abdominal dis-
comfort (item 34), ﬂushing (item 31), gas (item 36),
energy/tiredness (item 18), appetite and eating (items
13 and 38), and night sweats (item 33). In addition,
the QLQ-GI.NET21 addresses limitations to hobbies
or other leisure activities (item 7) and interference
with social activities (item 27).
The interviews support the selection of a deﬁnition
of clinically meaningful change for Phase III clinical766development: a 30% reduction in bowel movement
frequency experienced for at least half of the days
during the double-blind treatment period.
The results of this study suggest limitations in the
EORTC QLQ-C30 and GI.NET21 in assessing
patients with CS. The greatest priority of patients
was reducing bowel movement frequency, which is
captured in only 1 domain. The overall EORTC-
QLQ-C30 may not be expected to show statistically
signiﬁcant improvement because it includes 30 items
and provides equal weight to all of them. The domains
include concepts such as ﬁnancial worries that are not
necessarily related to treatment. A validation study of
the EORTC QLQ-C30 and GI.NET21 showed re-
sponsiveness on the subscales of diarrhea, appetite
loss, disease-related worries, and social functioning
when patients initiated antitumor therapy, while
several other domains showed little change.15
Therefore, a strategy of repeating the interviews in
Phase III of development of telotristat etiprate was
chosen as a means of supplementing the standardized
questionnaire. The interviews in Phase III were to be
done prospectively at the time of completion of
double-blind treatment. Patients were to be inter-
viewed only once (no baseline interview) to minimize
their burden. The interviews were to include questions
about whether the changes that patients experienced
were meaningful, and participant responses would be
analyzed in relation to the objective data on bowel
movement frequency obtained from electronic diaries.
The results of the present study should be inter-
preted with consideration of a few limitations. First,
the study comprised a fairly small sample of 11
participants, and only those patients who had partici-
pated in the earlier clinical trial were eligible for the
interview study. Second, only 2 of 7 centers that
enrolled patients into the Phase II trial agreed to
participate in the patient interview study, thus reduc-
ing the number of potentially eligible participants
from 23 to 16. At the time of the interviews, only 4
of the participants were in the open-label phase of the
clinical trial, while the others had completed their trial
participation; thus, recall accuracy and bias may have
been issues as, for most patients, there was a long gap
between study participation and the interview. This
time lag (42 years for several individuals) was related
to the processes of interview protocol development
and ethics committee approval, which were initiated
after the results from the double-blind portion becameVolume 38 Number 4
H.L. Gelhorn et al.available. However, most of the patients appeared to
have had very good and detailed recollections of their
experiences, as evidenced by the detailed and consis-
tent descriptions of their symptom and treatment
experiences that they were able to provide during
the interviews. As CS is very rare, a qualitative
approach with interviews has been highly informative.
Finally, those who agreed to participate in the inter-
views may have been more willing to participate due
to a positive response to therapy, and further, those
who were participating in the open-label extension
phase of the study were obviously aware of their
treatment status.
The results of this study were included in a con-
structive dialogue with the US Food and Drug Admin-
istration (FDA) about clinically meaningful change and
the choice of the primary end point for Phase III. The
FDA accepted the interview results as a part of an
overall dossier that served to deﬁne clinically mean-
ingful change. In this respect, the exercise provides
useful information and an example of how patient-
reported outcomes can support a clinical development
program and an overall regulatory strategy, even if they
are not intended for a speciﬁc role of labeling.
The exercise is also consistent with guidance on
patient-reported outcomes issued by the FDA.14 In
particular, the FDA encourages the development of an
end point model. The interview approach in this study
can form the basis of a model by connecting different
signs, symptoms, and patient-reported outcomes: high
bowel movement frequency is a central issue for
patients, and it directly affects the ability of patients to
enjoy life and participate in social and physical activities.
More broadly, the interviews reﬂect greater patient
engagement in the conduct of clinical research. The
value of this engagement is increasingly recognized
and supported by groups such as the Patient Centered
Outcomes Research Institute.16
The approach used for this study may be helpful
for other conditions. Common practice now includes
holding focus groups with patients early in clinical
development and piloting patient-reported outcomes
assessments in Phase II. Yet focus groups are not
always conducted early, and the size of the patient
population for rare diseases may not support recruit-
ment of individuals for this purpose. Furthermore, it
may be difﬁcult to select or reject instruments based
on quantitative data from small numbers of patients in
Phase II studies. In such cases, a detailed qualitativeApril 2016assessment based on patient interviews that are con-
ducted in parallel with the trial may be the most
feasible and informative approach to the identiﬁca-
tion, selection, and reﬁnement of appropriate end
points and their corresponding measures. Even in
larger-scale Phase III trials, direct interviews may
identify patients’ priorities more effectively and pro-
vide a better context for interpreting clinically mean-
ingful change than standardized questionnaires, or
may perhaps provide a complementary approach.CONCLUSIONS
The ﬁndings from this qualitative interview study suggest
that bowel movement frequency in patients with CS is a
clinically relevant end point with a signiﬁcant impact on
patients’ lives. The results also suggest that telotristat
etiprate may improve key aspects of CS that are impor-
tant to patients. These observations have guided the
selection of end points, instruments, and an interview
substudy in the Phase III clinical program for telotristat
etiprate. The approach described for identifying relevant
symptoms and their impact on daily life may be relevant
to patient-reported outcomes strategies for other oncology
studies and studies of other rare conditions.ACKNOWLEDGMENTS
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